BRUKINSA fuels growth, but patents and clinical delays matter
- Q3 2026 total global product revenue reached $1.9 billion, growing 33% year-over-year.
- BRUKINSA produced $1.4 billion in Q3 2026 revenue, with U.S. sales crossing $1 billion for the first time.
- The solid tumor pipeline showed progress at ESMO, but the FDA requested more data for tacabrutideg.
- Management warned of incoming biosimilar and volume-based procurement headwinds for the Amgen portfolio beyond 2026.
- Generic challenges and lawsuits, including a patent fight over BRUKINSA tablets, pose real commercial risks.
A global leader facing clear hurdles
BeOne has built a global oncology business around BRUKINSA. The blood cancer therapy is the global revenue leader in the BTK inhibitor class. In Q3 2026, BRUKINSA global revenues reached $1.4 billion, which helped push total global product revenue to $1.9 billion, up 33% from the prior year. The U.S. market continues to dominate the growth profile.
The bull case focuses on sustained BRUKINSA growth and a maturing pipeline. BRUKINSA is capturing high numbers of new patient starts and benefits from real-world evidence showing a survival advantage. Beyond the core product, the solid tumor pipeline is advancing. Recent data presentations at ESMO for early-stage candidates show the pipeline is turning into a multi-modality engine.
The bear case centers on the vulnerability of relying heavily on one drug and the uncertainty of clinical data timelines. Zydus has filed to produce a generic version of BRUKINSA tablets, and AbbVie has sued over trade secrets related to a pipeline asset. Furthermore, the accelerated approval submission for the BTK degrader tacabrutideg in R/R CLL was delayed to mid-2027 following FDA requests for additional follow-up.
Discover, build, and distribute globally
BeOne discovers, develops, and sells targeted cancer treatments. The company relies on its internal sales teams in major markets like the U.S. and Europe, and uses partnerships, such as its deal with Amgen, to sell in-licensed products in China. The company is actively investing in domestic capabilities, recently announcing a $300 million expansion of its clinical and commercial manufacturing site in Hopewell, New Jersey.
Product sales drive the vast majority of revenue. In Q3 2026, total product revenue reached $1.9 billion. BRUKINSA was the dominant source, but other drugs like TEVIMBRA and Amgen partnered products also contributed significantly. The U.S. remains the largest market, generating over $1 billion in the quarter.
The model relies heavily on clinical success and patent protection. Cancer drug markets are highly competitive. Companies must constantly fund new trials to expand approvals and defend against generic or biosimilar drugs. As BeOne scales, legal challenges from generic makers and supply chain complexities across the U.S., China, and Europe become larger factors.
The core franchise and new bets
BRUKINSA
The primary revenue driver. It treats various blood cancers and generated $1.4 billion globally in Q3 2026.
TEVIMBRA
An immuno-oncology drug approved for certain esophageal and gastric cancers, generating $243 million in Q3 2026.
BEQALZI
An FDA-approved BCL-2 inhibitor for relapsed or refractory mantle cell lymphoma.
Sonrotoclax
A BCL2 inhibitor with early approvals in China. It is being tested in combinations aiming for fixed-time cancer treatments.
Tacabrutideg
A BTK degrader targeting relapsed or refractory CLL, with an accelerated approval submission now planned for mid-2027.
Amgen in-licensed products
Products like XGEVA and KYPROLIS that generate meaningful sales in China through a strategic partnership.
Revenue depends heavily on one drug
Mix is based on Q3 2026 total global product revenues of $1.9 billion. BRUKINSA represents approximately 74% of total sales.
What could derail the story
Generic BRUKINSA tablet challenge
High impact · Medium oddsZydus filed an application seeking FDA approval for a generic version of BRUKINSA tablets, leading to a patent lawsuit in early 2026. A loss could shorten the protected life of BeOne's biggest drug.
AbbVie trade secret lawsuit
Medium impact · Medium oddsAbbVie claims BeOne misused trade secrets for the BGB-16673 BTK degrader program. Litigation can consume resources and potentially restrict a key pipeline asset.
Geopolitical supply chain stress
Medium impact · Medium oddsOperating across the U.S., China, and Europe exposes the company to tariffs and import controls. U.S. regulatory scrutiny on imported pharmaceuticals remains an ongoing concern, though domestic expansions mitigate some risk.
Biosimilar competition for partnered drugs
Low impact · High oddsManagement noted incoming biosimilar competition and volume-based procurement risks for XGEVA and KYPROLIS within their Amgen partnered portfolio, which will likely compress sales growth beyond 2026.
In one breath
What does BeOne Medicines do?
BeOne Medicines discovers, develops, and sells targeted cancer treatments. Its most successful product is BRUKINSA, a therapy for blood cancers.
Why is BRUKINSA important?
BRUKINSA generated $1.4 billion in Q3 2026, representing about 74% of total product revenue. The company's financial success is heavily tied to this single drug.
What is happening with Tacabrutideg?
Tacabrutideg is an experimental BTK degrader. The company delayed its accelerated approval submission from late 2026 to mid-2027 following FDA requests for additional follow-up data.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near BeOne Medicines AG in Finn's Biotechnology industry ranking.

